Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Polaris Venture Capital is committed to building successful enterprises through value-added partnerships with promising technology companies. With the recent closing of Polaris Fund III, and the merger of the management team of Polaris with the Eucalyptus Ventures management team, Polaris Venture Capital is by far the largest and most experienced venture capital management group originating in Israel. Possessing vast experience in equity investments and high-technology management, Polaris Venture Capital is now managing over $700 million.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
6/2005 | ClearView Audio | Series A | 7M |
8/2008 | ClearView Audio | Venture Round | 4M |
3/2015 | aTyr Pharma | Series E | 76M |
5/2007 | ClearView Audio | Venture Round | 3M |
2/2001 | Phonetic Systems | Private Equity Round | 0 |
12/2017 | Respicardia | Venture Round | 0 |
5/2008 | Selecta Biosciences | Seed Round | 2.5M |
3/2013 | Avitide | Series A | 1.4M |
7/2009 | Avila Therapeutics | Series B | 30M |
8/2000 | SercoNet | Series B | 5M |
11/1999 | Vigil Technologies, Inc. | Series B | 5.5M |
6/2013 | Ocular Therapeutix | Series D | 23.8M |
3/2019 | NakedPoppy | Seed Round | 4.1M |
2/2021 | Seraxis | Series C | 40M |
2/2006 | Imprivata | Series B | 12M |
5/2017 | Cardlytics | Series G | 0 |
10/2000 | Ingenium Pharmaceuticals AG | Series B | 44M |
3/2006 | Allurent | Series A | - |
9/2018 | Lyra Therapeutics | Series B | 0 |
2/2021 | Seraxis | Series C | 0 |
3/2019 | NakedPoppy | Seed Round | 0 |
9/2018 | Lyra Therapeutics | Series B | 0 |
12/2017 | Respicardia | Venture Round | 0 |
5/2017 | Cardlytics | Series G | 0 |
3/2015 | aTyr Pharma | Series E | 0 |
6/2013 | Ocular Therapeutix | Series D | 0 |
3/2013 | Avitide | Series A | 0 |
7/2009 | Avila Therapeutics | Series B | 0 |
8/2008 | ClearView Audio | Venture Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|